Immatics (NASDAQ:IMTXW) Short Interest Up 7.1% in September

Immatics (NASDAQ:IMTXW) saw a significant growth in short interest in September. As of September 15th, there was short interest totalling 1,500 shares, a growth of 7.1% from the August 31st total of 1,400 shares. Based on an average daily volume of 1,200 shares, the days-to-cover ratio is currently 1.3 days.

Immatics Trading Down 6.1 %

Shares of NASDAQ IMTXW opened at $2.16 on Wednesday. The company’s 50-day simple moving average is $2.64 and its 200-day simple moving average is $2.79. Immatics has a 52-week low of $1.60 and a 52-week high of $4.14.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.